Schizo Affective Disorder
71
13
16
35
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Published Results
19 trials with published results (27%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
5.6%
4 terminated out of 71 trials
89.7%
+3.2% vs benchmark
14%
10 trials in Phase 3/4
54%
19 of 35 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 35 completed trials
Clinical Trials (71)
D-serine AudRem: R33 Phase
REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
Examining the Efficacy of a Virtual Reality Cognitive Remediation Program for People Living With Psychosis
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Technology-Assisted Implementation of a Mobile Health Program for Serious Mental Illness
CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies
Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA
Visual Perception in Schizophrenia
Ketogenic Diet in People With Schizophrenia
Causal Lesion Network Guided Treatment of Bipolar Mania With Transcranial Electrical Stimulation
Remote State Representation in Early Psychosis
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
EPI-MINN: Targeting Cognition and Motivation - National
Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)